Medpace Holdings (MEDP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Medpace Holdings

NasdaqGS•Healthcare•Diagnostics & Research

$620.48+25.07(0.04%)After hours

Market Cap

$17.25B

P/E

35.1x

P/S

6.2x

P/B

39.8x

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

How this company scores

ExcellentMetricSide Score: 89/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability24/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 35.1x5y range 21.4x – 43.4x

Currently near its 20-quarter median.

P/S · 6.2x5y range 3.5x – 6.9x

Currently above its 20-quarter median.

P/B · 39.8x5y range 7.5x – 52.1x

Price & Volume

Market Cap $17.25B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.78B
Q. Revenue: $707.33M
TTM EBITDA: $611.20M
TTM Op. Income: $583.40M
Q. Op. Income: $146.82M
TTM Net Income: $491.50M
Q. Net Income: $121.36M
EPS: $4.31
Shares Out.: $28.17M

$2.78B in TTM revenue grew 24.7% YoY, reaching $707.33M last quarter. TTM EBITDA of $611.20M and TTM operating income of $583.40M show growth is flowing through to the bottom line. TTM net income of $491.50M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 21.7%
Op. Margin: 20.8%
Net Margin: 17.2%

Op. margin of 20.8% is down 0.2% YoY — costs are rising relative to revenue. Net margin at 17.2% Over the past year, operating margin is down 1% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 35.1x
P/S Ratio: 6.2x
P/B Ratio: 39.8x

At 35.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.2x and P/B of 39.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 64% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.06B
Cash: $502.69M
Long-Term Debt: N/A
Book Value: $433.86M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $162.01M
TTM Free Cash Flow: $706.69M
FCF Margin: 25.4%
FCF / Net Income: 1.4

TTM FCF of $706.69M on $162.01M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 22% — a weakening trend.